Description: <b>Iodine</b> deficiency can lead to thyroid enlargement (goiter) and hypothyroidism. In severe cases, longstanding iodine deficiency has been linked to an increased risk of developing certain thyroid disorders, including thyroid nodules and, less frequently, thyroid cancer.<br>
<br>
-Preliminary clinical research have suggested that molecular iodine may have antioxidant properties, modulate cell differentiation, and even exert antiproliferative effects in certain tissues.<br>
-"antineoplasic effect of I(2) in mammary cancer involves the intracellular formation of 6-IL. Mammary cancer cells are known to contain high concentrations of AA, which might explain why I(2) exerts apoptotic effects at lower concentrations only in tumoral cells."<a href="https://pubmed.ncbi.nlm.nih.gov/18827038/">ref</a>
<p><b>Iodine</b> — an essential halogen trace element required for thyroid-hormone synthesis and present biologically mainly as iodide (I−). For cancer-related research, the chemically distinct form with the strongest non-radioactive experimental evidence is <b>molecular iodine (I2)</b>, whereas iodide and radioactive iodine (especially 131I) have substantially different pharmacology and therapeutic roles. Iodine is formally classified as an essential micronutrient/trace element; standard abbreviations include I, I− for iodide, I2 for molecular iodine, and 131I for radioactive iodine. Dietary iodine originates principally from iodized salt, seafood, dairy products, seaweed, and supplements. Molecular I2 has demonstrated antiproliferative and adjuvant effects particularly in mammary/breast cancer models, but this should not be generalized to ordinary dietary iodide.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Formation of antineoplastic iodolipids, particularly 6-iodolactone from arachidonic acid, with subsequent PPARγ activation and differentiation/apoptotic signaling.</li>
<li>Induction of mitochondrial apoptosis through mitochondrial membrane depolarization, Bax activation, Bcl-2 suppression, thiol depletion, and apoptosis-inducing factor signaling.</li>
<li>Antiproliferative and cell-cycle effects, with preferential effects reported in mammary cancer cells relative to normal mammary cells at moderate I2 concentrations.</li>
<li>Chemosensitization, including suppression of Bcl-2/MDR-related chemoresistance phenotypes and increased responsiveness to anthracycline-containing chemotherapy.</li>
<li>Suppression of angiogenic and invasive signaling, including reductions in VEGF, vascular density, uPA, EMT-associated phenotypes, and invasive capacity in breast-cancer models.</li>
<li>Modulation of the tumor immune microenvironment, including increased Th1-associated signaling, IFNγ/T-BET expression and immune-cell infiltration with suppression of TGF-β signaling in human breast tumors.</li>
<li>Redox modulation: molecular iodine can perturb tumor-cell thiol/redox homeostasis and mitochondrial signaling while also showing antioxidant effects in some normal tissues and in-vivo models; the direction is strongly context-dependent.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Dietary iodide is efficiently absorbed and distributed extracellularly, with substantial thyroid uptake through the sodium/iodide symporter and predominant renal elimination. Molecular I2 behaves differently from iodide in mammary tissue: experimental breast-cancer cells can take up I2 through a mechanism largely independent of NIS and incorporate iodine into lipids and proteins. The human breast-cancer studies used approximately 5 mg/day molecular I2, substantially above ordinary nutritional requirements and above the 1.1 mg/day adult tolerable upper intake level established for routine dietary exposure. Therefore anticancer-dose I2 should not be equated with nutritional iodine supplementation.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic breast-cancer experiments use approximately 10–200 µM molecular I2, including 200 µM in chemoresistance experiments. Direct equivalence between these culture concentrations and plasma iodine concentrations after oral dosing is not established because I2 is chemically reactive, undergoes reduction and organification, and can generate tissue-localized iodolipids. Consequently, high-concentration in-vitro observations should not be assumed to represent achievable systemic free-I2 exposure. Human evidence instead comes from oral dosing of 5 mg/day I2 and tumor-tissue endpoints.</p>
<p><b>Clinical evidence status:</b> Small human randomized/Phase II breast-cancer evidence plus substantial preclinical evidence. A randomized pilot study using 5 mg/day molecular I2 alone or with FEC/TE chemotherapy reported increased tumor responses, apoptosis and immune infiltration and reduced chemoresistance/toxicity signals, but the study was small and requires independent confirmation. ClinicalTrials.gov NCT03688958 remains listed with unknown status and has not been updated since 2018. Molecular iodine is not an established standard anticancer therapy. Separately, radioactive 131I is an established, regulated treatment for iodine-avid differentiated thyroid carcinoma; this is a fundamentally different therapeutic modality and should not be interpreted as evidence for non-radioactive iodine supplementation.</p>
<h3>Iodine Cancer-Relevant Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Iodolipid formation / 6-iodolactone / PPARγ</td>
<td>↑ 6-iodolactone; ↑ PPARγ; ↓ PPARα</td>
<td>Lower 6-iodolactone formation reported in normal mammary tissue</td>
<td>Antiproliferation, differentiation and apoptosis</td>
<td>Central proposed mechanism for molecular I2 in mammary cancer. Tumor enrichment in arachidonic acid may favor local formation of 6-iodolactone.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial apoptosis / Bax / Bcl-2 / AIF</td>
<td>↑ Bax; ↓ Bcl-2; ↓ mitochondrial membrane potential; ↑ AIF nuclear translocation; ↑ apoptosis</td>
<td>Less apoptosis at moderate concentrations; apoptosis can occur at higher concentrations</td>
<td>Selective mitochondrial cell death</td>
<td>Molecular iodine can initiate caspase-dependent or caspase-independent apoptosis depending on model and experimental conditions.</td>
</tr>
<tr>
<td>3</td>
<td>Proliferation / cell cycle</td>
<td>↓ proliferation; ↑ cell-cycle arrest; ↑ apoptosis</td>
<td>↑ G1 and G2/M arrest at moderate I2 exposure; apoptosis primarily at higher exposure</td>
<td>Growth suppression</td>
<td>Preferential tumor-cell cytotoxicity has been demonstrated in mammary models, but selectivity is concentration-dependent.</td>
</tr>
<tr>
<td>4</td>
<td>Chemosensitization / drug resistance</td>
<td>↓ Bcl-2; ↓ MDR-associated phenotype; ↑ doxorubicin retention; ↑ chemotherapy response</td>
<td>Potential ↓ chemotherapy-associated tissue injury (model-dependent)</td>
<td>Reduced chemoresistance</td>
<td>Supported by breast-cancer cell, rodent, canine and small human studies; strongest evidence concerns anthracycline-containing regimens.</td>
</tr>
<tr>
<td>5</td>
<td>Angiogenesis / VEGF / uPA</td>
<td>↓ VEGF; ↓ vascular density; ↓ uPA</td>
<td>Not established</td>
<td>Antiangiogenic activity</td>
<td>Demonstrated primarily in experimental mammary tumors.</td>
</tr>
<tr>
<td>6</td>
<td>EMT / invasion</td>
<td>↓ invasive phenotype; ↓ chemoresistant stem-like populations; ↓ EMT-associated phenotype</td>
<td>Not established</td>
<td>Reduced invasion and progression</td>
<td>Observed particularly in doxorubicin-resistant breast-cancer models and human tumor analyses.</td>
</tr>
<tr>
<td>7</td>
<td>Tumor immune response / Th1 / IFNγ / TGF-β</td>
<td>↑ T-BET; ↑ IFNγ; ↑ Th1/Th17-associated signaling; ↑ B-cell infiltration; ↓ TGF-β</td>
<td>Not established</td>
<td>Shift toward antitumor immune activity</td>
<td>Human tumor transcriptomic findings from the molecular-I2 breast-cancer study; clinical significance remains incompletely established.</td>
</tr>
<tr>
<td>8</td>
<td>Redox / cellular thiols / ROS</td>
<td>↓ cellular thiols; altered ROS signaling; ↑ mitochondrial stress (context-dependent)</td>
<td>Antioxidant effects reported in several tissues; oxidative toxicity possible at high exposure</td>
<td>Redox-dependent apoptosis and tissue protection</td>
<td>Iodine should not be classified simply as either a ROS inducer or antioxidant. Redox direction depends on chemical form, dose, tissue and baseline oxidative state.</td>
</tr>
<tr>
<td>9</td>
<td>I2 uptake / NIS independence</td>
<td>↑ I2 uptake and incorporation into lipids/proteins; largely NIS-independent in mammary cells</td>
<td>Lower uptake/retention in some normal-cell models</td>
<td>Enables tissue-localized iodine signaling</td>
<td>Distinct from iodide uptake through NIS and important when interpreting molecular-I2 studies.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Human signal demonstrated primarily in breast cancer</td>
<td>Excess iodine can cause thyroid dysfunction</td>
<td>Limits generalization and unsupervised high-dose use</td>
<td>Human I2 studies used 5 mg/day, above the routine adult dietary upper intake level. Susceptible individuals may develop iodine-induced hypothyroidism or hyperthyroidism. Evidence outside breast cancer is predominantly preclinical, and recent prostate models show potentially mixed anti- and pro-neoplastic effects.</td>
</tr>
</tbody>
</table>